Home › Prostate Cancer › Virginia › Richmond
Prostate Cancer clinical trials in Richmond, VA
19 studies for Prostate Cancer are looking for participants at sites in and around Richmond (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RecruitingPhase 3
- VCU Massey Comprehensive Cancer Center, Richmond
The Vanguard Study: Testing a New Way to Screen for Cancer
RecruitingHealthy volunteers welcome
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Bon Secours Richmond Community Hospital, Richmond
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- and 3 more
Distance-Based Exercise to Preserve Function and Prevent Disability
Recruiting
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Memorial Regional Medical Center, Mechanicsville · 6 mi away
- Bon Secours Saint Francis Medical Center, Midlothian · 11 mi away
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
RecruitingPhase 2
- Bon Secours Richmond Community Hospital, Richmond
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- and 4 more
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
RecruitingPhase 3
- VCU Massey Comprehensive Cancer Center, Richmond
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
RecruitingPhase 3
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Autonomic and Renal Contributions to Hypertension With ADT
RecruitingPhase 4Healthy volunteers welcome
- Virginia Commonwealth University, Richmond
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RecruitingPhase 3
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- and 4 more
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RecruitingPhase 3
- VCU Health Adult Outpatient Pavillion ( Site 0061), Richmond
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RecruitingPhase 3
- Bon Secours Cancer Institute at Saint Francis, Midlothian · 11 mi away
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RecruitingPhase 3
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- Virginia Commonwealth University/Massey Cancer Center, Richmond
- and 1 more
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Recruiting
- Virginia Urology Center, Richmond
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RecruitingPhase 3
- Bon Secours Richmond Community Hospital, Richmond
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- and 2 more
TERPS Trial for de Novo Oligometastic Prostate Cancer
RecruitingPhase 2
- Bon Secours Cancer Institute at St. Francis, Midlothian · 11 mi away
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RecruitingPhase 3
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
- Bon Secours Saint Francis Medical Center, Midlothian · 11 mi away
Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
RecruitingPhase 1/2
- Richmond Veterans Affairs Medical Center, Richmond
- Virginia Commonwealth University Massey Cancer Center, Richmond
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
RecruitingPhase 3
- VCU Massey Cancer Center at Stony Point, Richmond
- Virginia Commonwealth University/Massey Cancer Center, Richmond
Vitamin D for Prostate Endocrine Therapy
RecruitingPhase 3
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- and 3 more
About Prostate Cancer
Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.
More about Prostate Cancer on MedlinePlus
Prostate Cancer trials in other cities
- New York City, NY101 studies
- Houston, TX73 studies
- Los Angeles, CA64 studies
- Boston, MA56 studies
- Seattle, WA45 studies
- St. Louis, MO45 studies
- Chicago, IL45 studies
- Baltimore, MD45 studies
- San Francisco, CA44 studies
- Philadelphia, PA41 studies
- Nashville, TN40 studies
- Washington, DC39 studies
Other studies in Richmond
- Breast Cancer27 studies
- Non-Small Cell Lung Cancer26 studies
- Heart Failure17 studies
- Lung Cancer15 studies
- Cardiovascular Disease13 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Colorectal Cancer13 studies
- Cancer (all types)12 studies
- Metastatic Cancer12 studies
- Diffuse Large B-Cell Lymphoma11 studies
- Steatotic Liver Disease11 studies
- Melanoma11 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.